Most Read This Week
- Association Between Chronic Stress and Metastasis in Patients With Cancer
- Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
- Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
- Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer
- Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC
Recently Updated
- American Association for Cancer Research, April 5-10
- Tumor-Infiltrating Lymphocyte Abundance Prognostic in Early-Stage TNBC
- Detection of Serrated Polyps Improved With Propofol During Colonoscopy
- Improvement Seen in Survival With Adjuvant Pembrolizumab in Kidney Cancer
- Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia